Ceftazidime–avibactam treatment in bacteremia caused by OXA-48 carbapenemase-producing Klebsiella pneumoniae-Reference-Cited by-同舟云学术

Ceftazidime–avibactam treatment in bacteremia caused by OXA-48 carbapenemase-producing Klebsiella pneumoniae

Published:2022-08-08 Issue: Volume: Page:
ISSN:0934-9723
Container-title:European Journal of Clinical Microbiology & Infectious Diseases
language:en
Short-container-title:Eur J Clin Microbiol Infect Dis

Author:

Lima O.,Sousa A.,Longueira-Suárez R.,Filgueira A.,Taboada-Martínez C.,Portela-Pino C.,Nodar A.,Vasallo-Vidal F.,Martinez-Lamas L.,Pérez-Landeiro A.,Rubianes M.,Pérez-Rodríguez MT.

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Microbiology (medical),General Medicine,Microbiology (medical),Microbiology

Link

https://link.springer.com/content/pdf/10.1007/s10096-022-04482-9.pdf

Reference40 articles.

1. Poirel L, Héritier C, Tolün V, Nordmann P (2004) Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 48:15–22. https://doi.org/10.1128/aac.48.1.15-22.2004

2. Serra-Burriel M, Keys M, Campillo-Artero C, Agodi A, Barchitta M, Gikas A et al (2020) Impact of multi-drug resistant bacteria on economic and clinical outcomes of healthcare-associated infections in adults: systematic review and meta-analysis. PLoS ONE 15:e0227139. https://doi.org/10.1371/journal.pone.0227139

3. de Jonge BLM, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, Nichols WW (2016) In Vitro Susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible enterobacteriaceae isolates collected during the INFORM Global Surveillance Study (2012 to 2014). Antimicrob Agents Chemother 60:3163–3169. https://doi.org/10.1128/AAC.03042-15

4. Oteo J, Pérez-Vázquez M, Bautista V, Ortega A, Zamarrón P, Saez D et al (2016) The spread of KPC-producing Enterobacteriaceae in Spain: WGS analysis of the emerging high-risk clones of Klebsiella pneumoniae ST11/KPC-2, ST101/KPC-2 and ST512/KPC-3. J Antimicrob Chemother 71:3392–3399. https://doi.org/10.1093/jac/dkw321

5. Pitout JDD, Peirano G, Kock MM, Strydom K-A, Matsumura Y (2019) The global ascendency of OXA-48-type carbapenemases. Clin Microbiol Rev 18(33):e00102-e119. https://doi.org/10.1128/CMR.00102-19

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ceftazidime-Avibactam in the Treatment of Patients with Bacteremia or Nosocomial Pneumonia: A Systematic Review and Meta-analysis;Infectious Diseases and Therapy;2024-05-31

2. Indian consensus on the management of carbapenem-resistant enterobacterales infection in critically ill patients II (ICONIC II);Expert Review of Anti-infective Therapy;2024-05-27

3. Clinical Efficacy and Safety Evaluation of Ceftazidime-Avibactam in the Treatment of Klebsiella pneumoniae Infection: A Retrospective Analysis from a Hospital in China;Infection and Drug Resistance;2023-11

4. Production of OXA-48 carbapenemase acts as an independent risk factor for poor outcome in Klebsiella pneumoniae infection;European Journal of Clinical Microbiology & Infectious Diseases;2023-10-27

5. Pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam in peritoneal fluid in an orthotopic liver transplant recipient affected by bacteraemic complicated intra-abdominal infection due to OXA-181-producing Klebsiella pneumoniae;Journal of Global Antimicrobial Resistance;2023-09